<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8804207</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1862</journal-id>
<journal-id journal-id-type="nlm-ta">Schizophr Res</journal-id>
<journal-id journal-id-type="iso-abbrev">Schizophr. Res.</journal-id>
<journal-title-group>
<journal-title>Schizophrenia research</journal-title>
</journal-title-group>
<issn pub-type="ppub">0920-9964</issn>
<issn pub-type="epub">1573-2509</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30979669</article-id>
<article-id pub-id-type="pmc">7258307</article-id>
<article-id pub-id-type="doi">10.1016/j.schres.2019.03.010</article-id>
<article-id pub-id-type="manuscript">NIHMS1591805</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>NMDA receptor hypofunction for schizophrenia revisited: perspectives from epigenetic mechanisms</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Snyder</surname>
<given-names>Melissa A.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gao</surname>
<given-names>Wen-Jun</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, PA 19129</aff>
<aff id="A2"><label>2</label>Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, K1H 8M5</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Correspondence: <italic>Wen-Jun Gao, M.D., Ph.D.</italic>, Department of Neurobiology and Anatomy, Drexel University College of Medicine, 2900 Queen Lane, Philadelphia, PA 19129, Phone: (215) 991-8907, Fax: (215) 843-9802, <email>wg38@drexel.edu</email>; Melissa A. Snyder, Ph.D., <email>melbabayo@gmail.com</email></corresp>
<fn fn-type="COI-statement" id="FN1">
<p id="P30">Conflicts of Interests</p>
<p id="P31">The authors claim no financial and other conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>8</day>
<month>5</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>4</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>29</day>
<month>5</month>
<year>2020</year>
</pub-date>
<volume>217</volume>
<fpage>60</fpage>
<lpage>70</lpage>
<!--elocation-id from pubmed: 10.1016/j.schres.2019.03.010-->
<abstract id="ABS1">
<p id="P1">Schizophrenia (SZ) is a neurodevelopmental disorder with cognitive deficits manifesting during early stages of the disease. Evidence suggests that genetic factors in combination with environmental insults lead to complex changes to glutamatergic, GABAergic, and dopaminergic systems. In particular, the N-methyl-D-aspartate receptor (NMDAR), a major glutamate receptor subtype, is implicated in both the disease progression and symptoms of SZ. NMDARs are critical for synaptic plasticity and cortical maturation, as well as learning and memory processes. In fact, any deviation from normal NMDAR expression and function can have devastating consequences. Surprisingly, there is little evidence from human patients that direct mutations of NMDAR genes contribute to SZ. One intriguing hypothesis is that epigenetic changes, which could result from early insults, alter protein expression and contribute to the NMDAR hypofunction found in SZ. Epigenetics is referred to as modifications that alter gene transcription without changing the DNA sequence itself. In this review, we first discuss how epigenetic changes to NMDAR genes could contribute to NMDAR hypofunction. We then explore how NMDAR hypofunction may contribute to epigenetic changes in other proteins or genes that lead to synaptic dysfunction and symptoms in SZ. We argue that NMDAR hypofunction occurs in early stage of the disease, and it may consequentially initiate GABA and dopamine deficits. Therefore, targeting NMDAR dysfunction during the early stages would be a promising avenue for prevention and therapeutic intervention of cognitive and social deficits that remain untreatable. Finally, we discuss potential questions regarding the epigenetic of SZ and future directions for research.</p>
</abstract>
<kwd-group>
<kwd>NMDA receptor hypofunction</kwd>
<kwd>prefrontal cortex</kwd>
<kwd>development</kwd>
<kwd>schizophrenia</kwd>
<kwd>epigenetics</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>